SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.75
−0.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 98.9M | 46.0M | 1.1M | 151.0K | — |
| Cost of Revenue | 421.0K | — | — | — | — |
| Gross Profit | 98.5M | 46.0M | 1.1M | 151.0K | — |
| Operating Expenses | |||||
| R&D Expense | 120.4M | 97.6M | 65.3M | 36.0M | 22.0M |
| SG&A Expense | 34.1M | 29.2M | 16.6M | 9.7M | 5.9M |
| General & Admin Expense | 34.1M | 29.2M | 16.6M | 9.7M | 5.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (12.5M) | — | — | (47.6M) | — |
| Total Operating Expenses | 142.0M | 126.7M | 81.9M | (1.9M) | 28.0M |
| Cost and Expenses | 142.4M | 126.7M | 81.9M | (1.9M) | 28.0M |
| Operating Income (EBIT) | (43.5M) | (80.8M) | (80.8M) | 2.1M | (28.0M) |
| Non-Operating | |||||
| Interest Income | 20.7M | 19.5M | 8.6M | 2.8M | 291.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 20.7M | 19.5M | 8.6M | 2.8M | 291.0K |
| Other Non-Op Income/Expense | 20.6M | 31.9M | 8.5M | 2.8M | 291.0K |
| Non-Operating Income (excl Interest) | (2.6M) | (31.9M) | (8.5M) | 47.6M | — |
| EBT (Pre-Tax Income) | (22.9M) | (48.9M) | (72.3M) | 4.9M | (27.7M) |
| Income Tax Expense | 1.3M | 12.0K | (498.0K) | 691.0K | — |
| Bottom Line | |||||
| Net Income | (24.2M) | (48.9M) | (71.8M) | 4.2M | (27.7M) |
| Earnings from Cont. Ops | (24.2M) | (48.9M) | (71.8M) | 4.2M | (27.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.2M) | (48.9M) | (71.8M) | 629.0K | (27.7M) |
| Per Share | |||||
| Basic EPS | ($0.54) | ($1.10) | ($1.93) | $0.03 | ($1.42) |
| Diluted EPS | ($0.54) | ($1.10) | ($1.93) | $0.03 | ($1.42) |
| Revenue Per Share | $2.20 | $1.04 | $0.03 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 45.0M | 44.3M | 37.2M | 19.5M | 19.5M |
| Diluted Shares Outstanding | 45.0M | 44.3M | 37.2M | 19.5M | 19.5M |
| Profitability Metrics | |||||
| EBITDA | (39.8M) | (47.3M) | (70.9M) | (44.7M) | (27.4M) |
| D&A | 1.2M | 1.6M | 1.4M | 848.0K | 577.0K |
| EBIT | (41.0M) | (48.9M) | (72.3M) | (45.5M) | (28.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026